Retoz 90 mg 90 mg is a tablet product of MST Pharma and Healthcare Ltd. that contains Etoricoxib. Retoz 90 mg is used to relieve symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis.
There are 90 brands of Etoricoxib listed in Bangladesh. By unit price, Retoz 90 mg is among the cheapest of them.
What is Retoz 90 mg Tablet?
Retoz 90 mg 90 mg tablet is a medicine made by MST Pharma and Healthcare Ltd. This medicine is not suitable for everyone, and it is not meant to be started without medical advice. Doctors use it for the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pain and inflammation of acute gouty arthritis. The dose and duration are set by the doctor based on your condition.
Uses of Retoz 90 mg
Retoz 90 mg is used to relieve symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. Your doctor will decide if it is suitable for you.
How to use Retoz 90 mg
Take Retoz 90 mg exactly as your doctor prescribes. Swallow the tablet with water. Retoz 90 mg is taken by mouth. Do not take more than prescribed. Do not change the dose or stop on your own.
Side effects of Retoz 90 mg
Less common effects include dry mouth, taste changes, mouth ulcers, appetite or weight changes, chest pain, flushing, cough, shortness of breath, nosebleeds, anxiety, reduced mental alertness, tingling, electrolyte disturbance, muscle pain and joint pain. Like other NSAIDs, Retoz 90 mg 90 mg tablet can cause side effects in some people. Common side effects may include palpitations, fatigue, flu-like symptoms, and bruising. Tell your doctor if you notice any side effects. Contact your doctor if you experience any side effect that bothers you.
Safety and precautions
Etoricoxib is not suitable for everyone. It should not be used during pregnancy or breastfeeding, or by anyone with an active stomach ulcer or gastrointestinal bleeding, severe liver or kidney problems, heart failure, inflammaRetoz 90 mg bowel disease, or a hisRetoz 90 mg of allergic-type reactions to aspirin or NSAIDs. Keep out of reach of children.
Frequently asked questions
What is Retoz 90 mg used for?
Retoz 90 mg is used to relieve symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. Your doctor will decide if it is suitable for you.
How should I take Retoz 90 mg?
Take Retoz 90 mg exactly as your doctor prescribes. Swallow the tablet with water.
Can Retoz 90 mg cause side effects?
Less common effects include dry mouth, taste changes, mouth ulcers, appetite or weight changes, chest pain, flushing, cough, shortness of breath, nosebleeds, anxiety, reduced mental alertness, tingling, electrolyte disturbance, muscle pain and joint pain. Like other NSAIDs, Retoz 90 mg 90 mg tablet can cause side effects in some people.
Who should be careful with Retoz 90 mg?
Etoricoxib is not suitable for everyone. It should not be used during pregnancy or breastfeeding, or by anyone with an active stomach ulcer or gastrointestinal bleeding, severe liver or kidney problems, heart failure, inflammaRetoz 90 mg bowel disease, or a hisRetoz 90 mg of allergic-type reactions to aspirin or NSAIDs.
Etoricoxib is indicated for the symptomatic relief of-
Osteoarthritis (OA)
Rheumatoid arthritis (RA)
Ankylosing spondylitis, and
The pain and signs of inflammation associated with acute gouty arthritis.
For the short-term treatment of moderate pain associated with dental surgery.
Pharmacology
Etoricoxib is a potent, orally active cyclooxygenase-2 (COX-2) specific inhibitor within, and significantly above, the clinical dose range. Two isoforms of cyclooxygenase have been identified: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is responsible for prostaglandin-mediated normal physiologic functions such as gastric cytoprotection and platelet aggregation. Inhibition of COX-1 by nonselective NSAIDs has been associated with gastric damage and inhibition of platelet aggregation. COX-2 has been shown to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. Selective inhibition of COX-2 by etoricoxib (within the clinical dose range) decreases these clinical signs and symptoms with decreased potential for Gl toxicity and effects on platelet aggregation. Etoricoxib produced dose-dependent inhibition of COX-2 without inhibition of COX-1 at doses up to 150 mg daily. Etoricoxib did not inhibit gastric prostaglandin synthesis.
Dosage & Administration
Adult and adolescent over 16 years:
Osteoarthritis: The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy.
Rheumatoid arthritis: The recommended dose is 90 mg once daily.
Ankylosing spondylitis: The recommended dose is 90 mg once daily.
Acute gouty arthritis: The recommended dose is 120 mg once daily. In clinical trials for acute gouty arthritis, Etoricoxib was given for 8 days.
Postoperative dental surgery pain: The recommended dose is 90 mg once daily, limited to a maximum of 3 days.
Some patients may require additional postoperative analgesia. As the cardiovascular risks of Etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.
Interaction
With medicine:
Oral anticoagulants: In subjects stabilized on chronic warfarin therapy, the administration of Etoricoxib was associated with an increase in prothrombin time.
Diuretics, ACE inhibitors and Angiotensin II Antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs.
Acetylsalicylic Acid: Etoricoxib can be used concomitantly with acetylsalicylic acid at doses used for cardiovascular prophylaxis (low-dose acetylsalicylic acid).
Ciclosporin and tacrolimus: Although this interaction has not been studied with Etoricoxib, coadministration of ciclosporin or tacrolimus with any NSAID may increase the nephrotoxic effect of ciclosporin or tacrolimus.
With food & others: Take without regards to meals.
Contraindications
Hypersensitivity to the active substance or to any of the excipients.
Active peptic ulceration or active gastro-intestinai (Gl) bleeding.
Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
Pregnancy and lactation.
Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score 10).
Estimated renal creatinine clearance <30 ml/min.
Children and adolescents under 16 years of age.
Inflammatory bowel disease.
Congestive heart failure (NYHA ll-IV).
Patients with hypertension whose blood pressure is persistently elevated above 140/90 mmHg and has not been adequately controlled.
Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.
Side Effects
Side-effects may include palpitation, fatigue, influenza-like symptoms, ecchymosis; less commonly dry mouth, taste disturbance, mouth ulcer, appetite and weight change, atrial fibrillation, transient ischaemic attack, chest pain, flushing, cough, dyspnoea, epistaxis, anxiety, mental acuity impaired, paraesthesia, electrolyte disturbance, myalgia and arthralgia; very rarely confusion and hallucinations.
Pregnancy & Lactation
The use of Etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive. It is not known whether Etoricoxib is excreted in human milk. Etoricoxib is excreted in the milk of lactating rats. Women who use Etoricoxib must not breastfeed.
Precautions & Warnings
Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and Gl bleeding.
Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with Etoricoxib after careful consideration.
Administration of Etoricoxib may cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby impair renal function. Monitoring of renal function in such patients should be considered.
Caution should be exercised in patients with a history of cardiac failure, left ventricular dysfunction, or hypertension and in patients with pre-existing edema from any other reason.
Any patients with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormalliver function test has occurred, should be monitored. If signs of hepatic insufficiency occur, or if persistently abnormal liver function tests (three times the upper limit of normal) are detected, Etoricoxib should be discontinued.
Etoricoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
Etoricoxib may mask fever and other signs of inflammation. Caution should be exercised when co-administering Etoricoxib with warfarin or other oral anticoagulants.
Overdose Effects
Administration of single doses of Etoricoxib up to 500 mg and multiple doses up to 150 mg/day for 21 days did not result in significant toxicity. In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the Gl tract, employ clinical monitoring, and institute supportive therapy, if required.
Storage Conditions
Store at a temperature of below 30°C, protect from light & moisture. Keep out of reach of children.
Alternative brands of Etoricoxib
Other brands with the same generic name, cheapest first.